AIM OF WORK Azithromycin is a macrolide antibiotic used to treat bacterial infections. Today, it is marketed in the form of tablets, syrups, capsules and injections. One of the analytical tests carried out in the quality control of finished products of azithromycin is the analysis of impurities (related compounds and degradation products). The aim of this paper is to describe and explain chromatographic methods for analysis of impurities in azithromycin products which are used in their quality control. The similarities and differences of the methods are shown and compared with the pharmacopoeial methods for the analysis of azithromycin degradation products. MATERIALS AND METHODS Amount of degradation products may arise during the manufacture or storage of a pharmaceutical product and their content must be controlled. Azithromycin degradation products are analyzed by High Performance Liquid Chromatography (HPLC) in all types of dosage forms. In the analysis of azithromycin finished products UV detectors are used for detecting impurities in tablets, capsules and azithromycin injections, while the electrochemical detector (EC) is used to detect impurities in azithromycin syrups. The experimental conditions of the HPLC methods are described: stationary phase types, types and rates of mobile phase flow, gradient elution, detection methods, standard solution preparation and system suitability test. The tables show the chromatographic parameters used for the identification of degradation product peaks in azithromycin products. DISCUSSION Methods for analysis of degradation products in tablets, capsules and azithromycin injections use the same column, the same instrumental conditions, the same calibration and identification solutions. There is a difference in system suitability check requirements and attention should be paid if the samples of tablets, capsules or injections are analyzed together. If all the conditions for the system suitability test are checked, there are no obstacles to the analysis of these types of samples in parallel in the same system. Similar can be concluded for samples of azithromycin syrups. All dosages and formulations of the syrups can be analyzed together on the same system with an electrochemical detector if attention is paid to the fulfillment of all system suitability conditions. CONCLUSION In a regular analytics of pharmaceutical products in quality control labs it is of great importance that analyzes of different doses or formulations with the same active substance can be performed together on the same chromatographic system. If we compare the method for the analysis of azithromycin injections used in Pliva with those in Pharmacopoeia, it is apparent that the pharmacopoeia method is more complex and that it would probably take more days and more analysts to analyze degradation products in samples of azithromycin injections. This would reduce the laboratory's productivity and the number of analyzes performed in the unit of time, which ultimately can lead to a more expensive drug for the patient.